Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that ResMed Inc. made materially false and/or misleading statements and/or failed to disclose that: On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023. Analysts lowered their ratings in response to ResMed’s report, citing concerns over market share and gross margins. Following ResMed’s announcements, on August 4, 2023, ResMed’s stock price fell from $219.95 per share to $179.25 per share, a decline of more than $40 per share.
In order to be eligible to join the RMD class action lawsuit, you must have incurred a loss on shares of ResMed purchased during the class period listed above.
TOP
